Dr. Ghosh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1021 Morehead Medical Dr
Ste A
Charlotte, NC 28204Phone+1 980-442-2000Fax+1 704-355-5800
Summary
- I trained in Hematology and Oncology at Johns Hopkins University, School of medicine and stayed as faculty in Oncology after completion of my training. Since January 2014, I have lead the Lymphoma Division at Levine Cancer Institute, Carolinas HealthCare system.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2007 - 2010
Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 2004 - 2007
KJ Somaiya Medical CollegeClass of 1997
Certifications & Licensure
NC State Medical License 2013 - 2025
MD State Medical License 2008 - 2014- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma Start of enrollment: 2012 Apr 01
- Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma Start of enrollment: 2012 Apr 01
- Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2014 Mar 13
Publications & Presentations
PubMed
- 1190 citationsLisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, Matthew A. Lunning, Michael Wang
Lancet. 2020-09-19 - 80 citationsLisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transpla...Alison Sehgal, Daanish Hoda, Peter A Riedell, Nilanjan Ghosh, Mehdi Hamadani
The Lancet. Oncology. 2022-08-01 - 20 citationsTwo-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.Jeremy S Abramson, M Lia Palomba, Leo I Gordon, Matthew Lunning, Michael Wang
Blood. 2024-02-01
Journal Articles
- CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s LymphomaMark P Chao, Sonali M Smith, Ranjana Advani, Ian Flinn, Ravindra Majeti, Nancy L Bartlett, Leslie Popplewell, Justin Kline, Nilanjan Ghosh, Ann LaCasce, The New England Journal of Medicine
Abstracts/Posters
- Outcomes Following Early Relapse in Patients with Mantle Cell LymphomaNilanjan Ghosh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell LymphomaNilanjan Ghosh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell LymphomaNilanjan Ghosh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Chronic Lymphocytic Leukemia Treatment Patterns, Dosing, and Sequencing in the Era of Novel Targeted Therapies: Interim Analysis Results from the Prospective informCLL...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Chronic Lymphocytic Leukemia Treatment Patterns, Dosing, and Sequencing in the Era of Novel Targeted Therapies: Interim Analysis Results from the Prospective informCLL...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- De-Escalation of Antimicrobials in Adult Hematopoietic Cell Transplantation Recipients with Febrile Neutropenia of Unknown Origin2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
Common Conditioning Regimen Has Highest Mortality Risk, Lowest OS for NHL Patients Undergoing TransplantAugust 24th, 2020
Hands-on Approach Addresses Barriers to Care for DLBCL PatientsJanuary 20th, 2020
What’s in Store for CAR T Cell Therapy in Relapsed/Refractory Lymphoma?May 31st, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
